Personalised diabetes guidance. Powerful results.*
With diabetes management, one size doesn’t fit all. Every patient is unique, with changing goals, challenges, and needs.
That's why Dexcom provides individualised guidance - through a portfolio of products that can be adapted to each patient, and personalised education that is adapted to you.
Optimise therapy with the support of individualised guidance
Set custom goals and tap into built-in glycaemic metrics, like fasting glucose, for more timely treatment adjustment.†,‡,§
Drive behaviour change
Can help improve glycaemic management with self-reported changes to diet and activity.1-5
Tailor protection and support to every patient
Help deliver personalised protection with a range of alerts,6 connected insulin options, and remote tracking that are linked to improved clinical7-11 and patient-reported12 outcomes.
#1 CGM brand in patient satisfaction##,23 and CGM adherence.##,24
Personalised learning. Personalised guidance. Powerful results.*
Dexcom Academy supports you at every stage of your CGM journey with a unique personalised learning experience. Join the community of healthcare professionals and explore clinical evidence, on-demand training, real-world patient case studies and much more —all tailored to your individual needs and learning preferences. Designed to help you provide the best care for your patients.
Connect with a Dexcom representative today.
Discover how Dexcom can help you deliver more individualised care.
Dexcom CGM is for people two years and older. Smart device sold separately. For a list of smart devices, visit dexcom.com/compatibility. *Results with Dexcom CGM have been proven in over 70 clinical studies, data available on clinicaltrials.gov. Dexcom Data on File, 2025. †Healthcare professionals should use information in the software in conjunction with other clinical information available to them. ‡Patients must log their fasting glucose in order for the HCP to see fasting glucose metrics. §Compared to SMBG. ||CGM was used in an AID system. ¶Low alert was used in the study to achieve reported results. # Finger pricks required for diabetes treatment decisions if symptoms or expectations do not match readings. **Results were obtained with Dexcom G7 and Dexcom ONE and are applicable to Dexcom ONE+ due to the identical Delay 1st Alert feature. ††Results obtained with Dexcom ONE+ survey, which shares the similar features and usability as Dexcom G7. ‡‡ In adults 65 years and older in a single study. §§ Results were obtained with a previous generation of Dexcom CGM systems and are applicable to Dexcom ONE+, Dexcom G7, given similar feature sets, performance, and usability. ||||Based on data from Optum Clinformatics(r). ## Compared to other leading CGM manufacturers.
1 Crawford et al. Diabetes Technol Ther. 2025;27(S2): e193. 2 Martens TW, et al. BMJ Open Diabetes Res Care. 2025;13(6):e005469. 3 Shields S, et al. Sci Rep. 2024;14(1):31990. 4 Crawford MA, et al. Diabetes. 2025; 74 (S1): 1927–LB. 5 Richardson K, et al. Int J Behav Nutr Phys Act. 2024;21(1):145. 6 Dexcom G7 User Guide, 2024. 7 Brown SA, et al. Diabetes Care. 2021;44(7):1630-1640. 8 Brown SA, et al. N Engl J Med. 2019;381(18):1707-1717. 9 Aly A, et al. Diabetes Technol. Ther. 2024;26(S2): A254-255. 10 Welsh JB, et al. Diabetes Therapy. 2019;10(2):751-755. 11 Acciaroli G, et al. Diabet Med. 2023;40(6):e15093. 12 Polonsky WH, et al. Diabetes Technol Ther. 2021;23(3):195-202. 13 Ebekozien O, et al.Diabetes Technol Ther. 2025;27(Supp 2):e51. 14 Karges B, et al. Lancet Diabetes Endocrinol. 2025;13(2):88-96. 15 Heinemann L, et al. Lancet. 2018;391(10128):1367-1378. 16 Dexcom survey among Type 1 and Type 2 CGM users who switched to Dexcom ONE+ in UK, Belgium and Spain. 2025. n=292. Data on File. 17 Bao et al. Diabetes Technol Ther. 2022;24(5):299-306. 18 Crawford M, et al. Diabetes Technol Ther. 2024; 26(S2): A223. 19 Parsiani R, et al. J Family Med Prim Care. 2025;14(2):790-795. 20 Lind N, et al. Diabetes Care. 2024;47(5):881-889. 21 Crawford MA, et al. Diabetes. 2023;72(S1):63–LB. 22 Nemlekar P, et al. Am J Manag Care. 2025;31(4):183-188. 23 Independent survey among patients with diabetes in the United States. 2025. n=483. Data on File. 24 Independent survey among patients with diabetes in the United States. 2025. n=330. Data on File.
Dexcom, Dexcom Clarity, Dexcom Follow, Dexcom One, Dexcom Share, Stelo, and any related logos and designmarks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries.